Virginia Retirement Systems Et Al Xencor Inc Transaction History

Virginia Retirement Systems Et Al

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Jul 11, 2023	SELL	$25.95 - $36.95 $33,735 - $48,035	-1,300 Reduced 5.58%	22,000 $613,000
Q4 2022 May 17, 2023	BUY	$24.79 - $30.86 $9,916 - $12,344	400 Added 1.75%	23,300 $607 Million
Q3 2022 May 16, 2023	BUY	$24.62 - $32.44 $563,798 - $742,876	22,900 New	22,900 $595 Million
Q3 2020 Nov 12, 2020	SELL	$30.09 - $43.02 $243,729 - $348,462	-8,100 Closed	0 $0
Q2 2020 Aug 12, 2020	BUY	$27.76 - $33.42 $224,856 - $270,702	8,100 New	8,100 $262,000
Q3 2019 Oct 22, 2019	SELL	$33.73 - $46.27 $573,410 - $786,590	-17,000 Closed	0 $0
Q2 2019 Jul 26, 2019	SELL	$29.6 - $40.93 $278,240 - $384,742	-9,400 Reduced 35.61%	17,000 $696,000
Q1 2019 Apr 25, 2019	BUY	$27.85 - $38.09 $47,345 - $64,753	1,700 Added 6.88%	26,400 $820,000
Q4 2018 Feb 07, 2019	BUY	$32.39 - $42.05 $51,824 - $67,280	1,600 Added 6.93%	24,700 $893,000
Q3 2018 Nov 02, 2018	SELL	$35.69 - $47.65 $299,796 - $400,260	-8,400 Reduced 26.67%	23,100 $900,000
Q2 2018 Aug 03, 2018	BUY	$28.41 - $42.41 $894,915 - $1.34 Million	31,500 New	31,500 $1.17 Million

214

71.8M

2.5K

7.9K

Ticker XNCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,698,100
Market Cap $1.09B
Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...

Get notified when there are updates to the investment portfolio of Virginia Retirement Systems Et Al, based on Form 13F filings with the SEC.

Stay updated on Virginia Retirement Systems Et Al with notifications on news.